Our recent study demonstrates that macrophage-derived SPP1 critically impairs CD8+ T cell infiltration into the tumor microenvironment (TME), thereby accelerating tumor progression and diminishing the efficacy of immune checkpoint inhibitor (ICI) therapy. This evidence concerns the gene SPP1 and neoplasm.